{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T18:39:12Z","timestamp":1777315152264,"version":"3.51.4"},"reference-count":73,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>Regulatory approval of B-cell maturation antigen (BCMA)-CD3 bispecific antibodies (BsAbs) has revolutionized the treatment of patients with heavily pretreated relapsed or refractory multiple myeloma. Label-recommended premedications and step-up dose (SUD) regimens are used to mitigate the incidence and severity of serious adverse events such as cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome. Hospitalization of patients during the SUD regimen is also recommended by the manufacturers to facilitate the rapid therapeutic management of adverse events that may arise. Administering these therapies in an inpatient hospital setting increases the costs of delivering care, creates patient inconvenience, and most importantly, reduces overall access to this class of medication. Thus, the practice of administering BCMA-directed BsAb SUD regimens in an outpatient (OP) setting is being slowly adopted at some community practice sites; however, the development of robust OP administration models for these therapies requires more data on the feasibility and safety of doing so. Herein, we describe the OP BsAb program developed at our independent community oncology practice, New England Cancer Specialists (NECS). The program was designed with the intent to reduce health care resource utilization, improve patient experience, and expand treatment access for patients living in remote or underserved areas while preserving a coordinated care model. We outline the operational infrastructure and workflow implemented at NECS to administer BCMA-directed BsAb therapy in an OP setting to patients drawn from a vast rural geography. Finally, based on our clinical experiences, we discuss the potential to expand OP administration programs to BsAb therapies for other malignancies.<\/jats:p>","DOI":"10.1200\/op-25-00585","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T19:59:10Z","timestamp":1776974350000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of a Model Program at an Independent Community Oncology Practice for the Outpatient Administration of B-Cell Maturation Antigen\u2013Directed Bispecific Antibody Step-Up Doses"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2089-535X","authenticated-orcid":true,"given":"Yonatan","family":"Resnick","sequence":"first","affiliation":[{"name":"New England Cancer Specialists, Westbrook, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Boland","sequence":"additional","affiliation":[{"name":"New England Cancer Specialists, Westbrook, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Winters","sequence":"additional","affiliation":[{"name":"New England Cancer Specialists, Westbrook, ME"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0337-y"},{"key":"e_1_3_6_4_2","first-page":"100466","article-title":"A tertiary care centre experience with elranatamab: A report of three cases","volume":"21","author":"Kakkar D","year":"2024","unstructured":"Kakkar D, Singh A, Pillai RH, et al: A tertiary care centre experience with elranatamab: A report of three cases. Leuk Res Rep 21:100466, 2024","journal-title":"Leuk Res Rep"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061791"},{"key":"e_1_3_6_6_2","volume-title":"Tecvayli (teclistamab-cqyv) [package insert]","year":"2024","unstructured":"Tecvayli (teclistamab-cqyv) [package insert]. Horsham, PA, Janssen, 2024"},{"key":"e_1_3_6_7_2","volume-title":"Elrexfio (elranatamab-bcmm) [package insert]","year":"2025","unstructured":"Elrexfio (elranatamab-bcmm) [package insert]. New York, NY, Pfizer, 2025"},{"key":"e_1_3_6_8_2","volume-title":"Lynozyfic (linvoseltamab-gcpt) [package insert]","year":"2025","unstructured":"Lynozyfic (linvoseltamab-gcpt) [package insert]. Tarrytown, NY, Regeneron, 2025"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01520-y"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208192"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_6_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210376"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2277850"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.165"},{"key":"e_1_3_6_18_2","first-page":"1","article-title":"Seamless navigation of bispecific therapies: Optimizing management and outpatient access with a focus on coordination","volume":"15","author":"Mahmoudjafari Z","year":"2024","unstructured":"Mahmoudjafari Z, Ali A, Davis J, et al: Seamless navigation of bispecific therapies: Optimizing management and outpatient access with a focus on coordination. J Adv Pract Oncol 15:1-16, 2024","journal-title":"J Adv Pract Oncol"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208825"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2024.2352856"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178908"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-189642"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.906"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179727"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP-24-00489"},{"key":"e_1_3_6_30_2","first-page":"36","article-title":"Operationalizing bispecific antibodies across academic and community oncology centers in hematologic malignancies","volume":"6","author":"Scott JD","year":"2024","unstructured":"Scott JD. Operationalizing bispecific antibodies across academic and community oncology centers in hematologic malignancies. Pharmacy Times 6:36-37, 2024","journal-title":"Pharmacy Times"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204361"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000970664.60500.7f"},{"key":"e_1_3_6_33_2","volume-title":"Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management","year":"2022","unstructured":"Best Practices in Expanding Access to Bispecific Antibodies and Adverse Event Management. Association of Cancer Care Centers, 2022. https:\/\/cdn.sanity.io\/files\/0vv8moc6\/accc-cancer\/ecc6b58de955d1868e8774c3a27773b8198e9ea0.pdf"},{"key":"e_1_3_6_34_2","volume-title":"You+Us","author":"Baylor Scott & White Health","year":"2026","unstructured":"Baylor Scott & White Health. You+Us. Baylor Scott & White Health, 2026. https:\/\/pages.bswhealth.com\/patients.html?utm_source=cellulartherapies.com&utm_medium=offline&utm_content=redirect"},{"key":"e_1_3_6_35_2","volume-title":"Expanding Access to Cellular and Bispecific Therapies. Considerations and Recommendations","year":"2023","unstructured":"Expanding Access to Cellular and Bispecific Therapies. Considerations and Recommendations. Association of Community Cancer Centers, 2023. https:\/\/higherlogicdownload.s3.amazonaws.com\/SITCANCER\/2c19e5a6-3adb-4d01-b46c-c01e11745b3a\/UploadedImages\/Policy\/SITC_ACCC_Expanding_Access_Workshop_Report.pdf"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e23212"},{"key":"e_1_3_6_37_2","volume-title":"Bispecific Antibody Toxicity, StatPearls. StatPearls Publishing Copyright \u00a9 2025","author":"Chennapragada SS","year":"2025","unstructured":"Chennapragada SS, Ramadas P: Bispecific Antibody Toxicity, StatPearls. StatPearls Publishing Copyright \u00a9 2025. Treasure Island, FL, StatPearls Publishing LLC, 2025"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.06.013"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14444"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010064"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070467"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1348955"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00043-3"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0228"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016911"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00963-y"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7517"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19504"},{"key":"e_1_3_6_50_2","unstructured":"NCCN: Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma V.2.2026. \u00a9 National Comprehensive Cancer Network Inc. 2025. NCCN.org"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19537"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03484-6"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2448898"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01282-0"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199978"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-208961"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.026"},{"key":"e_1_3_6_62_2","volume-title":"Presented at the NCODA International Fall Summit","author":"Donnellan W","year":"2023","unstructured":"Donnellan W, Lin S-W, Abbas J, et al: Use of bispecific T-cell engaging antibodies (BsAbs) in community practices: Multidisciplinary perspectives on developing logistics and workflow for cytokine release syndrome (CRS) management. Presented at the NCODA International Fall Summit. Orlando, FL, 2023"},{"key":"e_1_3_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_6_64_2","first-page":"20","article-title":"Teach-back: A simple technique to enhance patients' understanding","volume":"25","author":"Bodenheimer T","year":"2018","unstructured":"Bodenheimer T: Teach-back: A simple technique to enhance patients' understanding. Fam Pract Manag 25:20-22, 2018","journal-title":"Fam Pract Manag"},{"key":"e_1_3_6_65_2","doi-asserted-by":"publisher","DOI":"10.1097\/NJH.0000000000000492"},{"key":"e_1_3_6_66_2","volume-title":"Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract","author":"Scott SA","year":"2024","unstructured":"Scott SA, Roberts DL, Gupta V, et al: Feasibility and safety of outpatient model for administration of bispecific antibodies. Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract, 2024"},{"key":"e_1_3_6_67_2","unstructured":"ClinicalTrials.gov: Outpatient administration of teclistamab or talquetamab for multiple myeloma. https:\/\/clinicaltrials.gov\/study\/NCT05972135"},{"key":"e_1_3_6_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-207295"},{"key":"e_1_3_6_69_2","unstructured":"ClinicalTrials.gov: Outpatient and intermittent dosing of elranatamab in relapsed\/refractory multiple myeloma (EMBRACE). https:\/\/clinicaltrials.gov\/study\/NCT06421675"},{"key":"e_1_3_6_70_2","unstructured":"ClinicalTrials.gov: Self-administration of subcutaneous elranatamab in the patients' homes (ERICA). https:\/\/clinicaltrials.gov\/study\/NCT06015542"},{"key":"e_1_3_6_71_2","unstructured":"ClinicalTrials.gov: A study to evaluate adverse events of subcutaneous (SC) epcoritamab administered in the outpatient setting in adult participants with relapsed or refractory diffuse large B-cell lymphoma and classic follicular lymphoma. https:\/\/clinicaltrials.gov\/study\/NCT05451810"},{"key":"e_1_3_6_72_2","unstructured":"ClinicalTrials.gov: Study evaluating safety tolerability and pharmacokinetics (PK) of tarlatamab in adults with small cell lung cancer (SCLC). https:\/\/clinicaltrials.gov\/study\/NCT03319940"},{"key":"e_1_3_6_73_2","first-page":"19","article-title":"Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1","volume":"24","author":"Chiang AC","year":"2024","unstructured":"Chiang AC, Olmedo Garcia ME, Carlisle J, et al: Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. Immunooncol Technol 24:19, 2024","journal-title":"Immunooncol Technol"},{"key":"e_1_3_6_74_2","volume-title":"Geographic Barriers Impede Access to Novel Cancer Treatments","author":"Munz K","year":"2025","unstructured":"Munz K, Ayyappan S: Geographic Barriers Impede Access to Novel Cancer Treatments. AMJC, 2025. https:\/\/www.ajmc.com\/view\/geographic-barriers-impede-access-to-novel-cancer-treatments"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-25-00585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:44:26Z","timestamp":1777311866000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-25-00585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":73,"alternative-id":["10.1200\/OP-25-00585"],"URL":"https:\/\/doi.org\/10.1200\/op-25-00585","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"2025-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-25-00585"}}